Other authors27, 28 supported the use of epidermal growth factor receptor (EGFR)‐targeted therapy due to the presence of EGFR‐activating mutations in mixed LCNECs with an adenocarcinoma component, while Mairinger et al.29hypothized the use of anti‐angiogenetic‐targeted drugs in association with chemotherapy as the angiogenesis could be involved in LCNEC metastasization. The gene discussed is EGFR; the disease is large cell neuroendocrine carcinoma.